Kloske Courtney M, Forner Stefania, Meyers Emily A, Towers Albert E, Snyder Heather M, Carrillo Maria C
Medical and Scientific Relations and Medical Affairs, Alzheimer's Association, Chicago, Illinois, USA.
Alzheimers Dement. 2025 Jan;21(1):e14354. doi: 10.1002/alz.14354. Epub 2024 Dec 23.
Alzheimer's disease (AD) and related dementias (ADRD) present significant health challenges. Understanding their underlying biology, advancing existing and new therapies, and enhancing care for patients and caregivers are critical priorities.
This article utilizes data from the International Alzheimer's and Related Dementias Research Portfolio (IADRP) to analyze funding patterns from the Alzheimer's Association over the past decade.
As the largest nonprofit funder of AD/ADRD research globally, the Alzheimer's Association has committed over $430 million, supporting a diverse range of studies across the entire spectrum of dementia-related science. The funding landscape has evolved, reflecting new areas of investigation and collaboration with broader research initiatives.
This article highlights the dynamic nature of the Association's funding strategies and ongoing efforts to connect funding with additional supportive resources, thereby enhancing the overall research ecosystem Highlights As the world's largest nonprofit funder of Alzheimer's disease and dementia science, the Alzheimer's Association's funding activities are strategically designed in partnership with the global research community to address scientific gaps in our knowledge to advance research. A large part of the Association's funding portfolio depends on key partnerships and collaborations. From 2019 to 2023, the Alzheimer's Association has allocated funding for more than 850 new research studies. The diversity of areas funded is clear across the Association's portfolio. Beyond the Association's strong emphasis on supporting research through grant funding, there are also efforts to ensure the necessary ecosystem to support the career development of researchers and clinicians, maintaining ongoing support for current and future awardees, including convening and the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART).
阿尔茨海默病（AD）及相关痴呆症（ADRD）带来了重大的健康挑战。了解其潜在生物学机制、推进现有及新疗法，以及加强对患者和护理人员的照护是至关重要的优先事项。
本文利用国际阿尔茨海默病及相关痴呆症研究项目组合（IADRP）的数据，分析了阿尔茨海默病协会在过去十年的资助模式。
作为全球最大的非营利性AD/ADRD研究资助机构，阿尔茨海默病协会已投入超过4.3亿美元，支持了痴呆症相关科学全领域的各类研究。资助格局不断演变，反映了新的研究领域以及与更广泛研究计划的合作。
本文强调了该协会资助策略的动态性质，以及将资助与其他支持资源相联系的持续努力，从而加强了整体研究生态系统。要点：作为全球最大的阿尔茨海默病和痴呆症科学非营利性资助机构，阿尔茨海默病协会的资助活动是与全球研究界合作进行战略设计的，以填补我们知识中的科学空白，推动研究进展。该协会大部分资助项目依赖于关键的伙伴关系和合作。2019年至2023年期间，阿尔茨海默病协会为850多项新研究提供了资金。协会资助项目涵盖的领域多样性明显。除了协会大力强调通过资助来支持研究外，还努力确保有必要的生态系统来支持研究人员和临床医生的职业发展，持续为当前及未来的受奖者提供支持，包括召开会议以及阿尔茨海默病协会国际促进阿尔茨海默病研究与治疗协会（ISTAART）。
